Payment overview · 2025
General Payments
$208.66
13 reported records · 4 companies
Healthcare provider profile · identity verified
Frederic A Smith, MD
Allopathic & Osteopathic Physicians|Internal Medicine · IRMO, SC · NPI 1528029287
Verified facts
What the public records show
CMS Open Payments records show Frederic A Smith, MD received $208.66 in general payments during 2025 across 13 reported records.
Abbott Laboratories accounted for 57.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $120.15 | 57.6% | 8 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$44.65 | 21.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.93 | 10.5% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $21.93 | 10.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $208.66 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $44.65 | 3 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 518 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 118 |
| Alprazolam | Alprazolam | 264 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 260 | 43 |
| Omeprazole | Omeprazole | 257 | 74 |
| Losartan Potassium | Losartan Potassium | 249 | 72 |
| Sertraline Hcl | Sertraline Hcl | 238 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 69 |
| Lisinopril | Lisinopril | 218 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 56 |
| Metformin Hcl | Metformin Hcl | 163 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 53 |
| Simvastatin | Simvastatin | 161 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 42 |
| Gabapentin | Gabapentin | 145 | 41 |
| Irbesartan | Irbesartan | 139 | 42 |
| Allopurinol | Allopurinol | 127 | 36 |
| Famotidine | Famotidine | 123 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 112 | 32 |
| Furosemide | Furosemide | 107 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 32 |
| Trazodone Hcl | Trazodone Hcl | 106 | 26 |
| Ozempic | Semaglutide | 98 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 25 |
| Celecoxib | Celecoxib | 93 | 21 |
| Potassium Chloride | Potassium Chloride | 93 | 26 |
| Meloxicam | Meloxicam | 85 | 28 |
| Eliquis | Apixaban | 83 | 25 |
| Montelukast Sodium | Montelukast Sodium | 82 | 25 |
| Tramadol Hcl | Tramadol Hcl | 81 | 28 |
| Jardiance | Empagliflozin | 78 | 19 |
| Metformin Hcl Er | Metformin Hcl | 78 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 23 |
| Temazepam | Temazepam | 74 | 14 |
| Bupropion Xl | Bupropion Hcl | 70 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 23 |
| Mirtazapine | Mirtazapine | 66 | 15 |
| Valsartan | Valsartan | 66 | 19 |
| Prednisone | Prednisone | 65 | 31 |
| Januvia | Sitagliptin Phosphate | 62 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 23 |
| Glimepiride | Glimepiride | 60 | 17 |
| Atenolol | Atenolol | 59 | 15 |
| Clonazepam | Clonazepam | 59 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 13 |
| Carvedilol | Carvedilol | 53 | 15 |
| Chlorthalidone | Chlorthalidone | 51 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 43 |
| Benazepril Hcl | Benazepril Hcl | 50 | 12 |
| Finasteride | Finasteride | 50 | 18 |
| Lorazepam | Lorazepam | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 15 |
| Synthroid | Levothyroxine Sodium | 49 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 19 |
| Ezetimibe | Ezetimibe | 44 | 13 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 31 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 28 |
| Estradiol | Estradiol | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 12 |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | 15 |
| Rybelsus | Semaglutide | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 13 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 14 |
| Valacyclovir | Valacyclovir Hcl | 28 | 12 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | 11 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $208.66 · 13 records | Abbott Laboratories | CLOTTRIEVER BOLD CATHETER, INTELLIS ADAPTIVESTIM, VYNDAQEL | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error